Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Commentaries

How to Make Mice Tell the Truth

  1. Helen E. Thomas1,2⇑,
  2. Thomas C. Brodnicki1,2 and
  3. Thomas W.H. Kay1,2
  1. 1St Vincent’s Institute, Fitzroy, Victoria, Australia
  2. 2Department of Medicine, St Vincent’s Hospital, The University of Melbourne, Fitzroy, Victoria, Australia
  1. Corresponding author: Helen E. Thomas, hthomas{at}svi.edu.au.
Diabetes 2016 May; 65(5): 1161-1163. https://doi.org/10.2337/dbi16-0001
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Article Figures & Tables

Tables

  • Table 1

    Criteria for testing a therapeutic treatment in NOD mice

    • Ensure NOD females have a high incidence of diabetes (e.g., ≥70% diabetes incidence by 300 days of age) in the chosen animal facility if a preventative study is being performed
    • Establish an SOP and fixed study entry criteria for the treatment regimen
    • Perform a power calculation to determine the minimum cohort size required to detect an effect of the desired size
    • Determine what controls are required to evaluate treatment efficacy
    • Monitor diabetes incidence in controls contemporaneously with treated mice
    • Ensure cohorts are tested in a timely fashion to avoid variable diabetes incidences over a long period
    • Use pharmaceutical-grade reagents when possible
    • Generate sufficient reagent stocks for treatment of all mice to minimize effects due to different reagent preparations
    • Randomize treatment within age-matched littermates
    • Have the same experienced personnel perform the treatment and monitoring protocols for all mice
    • Ideally, these criteria should be identical for single-lab and multicenter trials. However, it is well recognized that initial testing of a proposed treatment by a single lab may not be optimal because of various factors (e.g., the most effective treatment protocol is not obvious, pharmaceutical-grade reagents are not readily available, or technical proficiency for performing treatment and monitoring protocols may be limited). This should not preclude the publishing of such studies as long as the caveats for the results are clearly described by the investigators. Indeed, the advantage of the NOD mouse model is that a promising treatment protocol can be further tested and potentially improved upon by other groups.

PreviousNext
Back to top
Diabetes: 65 (5)

In this Issue

May 2016, 65(5)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
How to Make Mice Tell the Truth
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
How to Make Mice Tell the Truth
Helen E. Thomas, Thomas C. Brodnicki, Thomas W.H. Kay
Diabetes May 2016, 65 (5) 1161-1163; DOI: 10.2337/dbi16-0001

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

How to Make Mice Tell the Truth
Helen E. Thomas, Thomas C. Brodnicki, Thomas W.H. Kay
Diabetes May 2016, 65 (5) 1161-1163; DOI: 10.2337/dbi16-0001
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Adipose Tissue Malfunction Drives Metabolic Dysfunction in Alström Syndrome
  • Staying Connected: Transcriptomics in the Search for Novel Diabetic Kidney Disease Treatments
  • Going in Early: Hypoxia as a Target for Kidney Disease Prevention in Diabetes?
Show more Commentaries

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.